Vidaza to Restore Hormone Thx Prostate
Public ClinicalTrials.gov record NCT00384839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a bone marrow disease. The pharmaceutical company involved in this study, Pharmion Corporation, is the manufacturer of Vidaza.
Study identification
- NCT ID
- NCT00384839
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2006 (Type not available)
- Primary completion
- Nov 2009 (Actual)
- Completion
- Nov 2009 (Actual)
- Last update posted
- Oct 25, 2018
2006 – 2009
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center-Midtown | Denver | Colorado | 80218 | — |
| Cancer Centers of Florida, P.A. | Ocoee | Florida | 34761 | — |
| Minnesota Oncology Hematology, P.A. | Minneapolis | Minnesota | 55404 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89109 | — |
| New York Oncology Hematology, P.C. | Albany | New York | 12208 | — |
| Raleigh Hematology Oncology Associates | Cary | North Carolina | 27511 | — |
| Northwestern Carolina Oncology Hematology | Hickory | North Carolina | 28602 | — |
| Texas Oncology, P.A. | Dallas | Texas | 75246 | — |
| Texas Oncology, P.A. | Fort Worth | Texas | 76104 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Deke Slayton Cancer Center | Webster | Texas | 77598 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Cancer Care Nrothwest-South | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00384839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2018 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00384839 live on ClinicalTrials.gov.